PhaseBio Pharmaceuticals Net Income

PhaseBio Pharmaceuticals (PHAS) currently reports a net income of $28M as of June 2022. That compares with $-110M in the prior-year period — up 125.0% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore PhaseBio Pharmaceuticals's net income history and peer comparisons.

PhaseBio Pharmaceuticals's net income increased from $-110M to $28M — a 125.0% year-over-year increase (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PhaseBio Pharmaceuticals's net income of $28M is lower than the Healthcare sector average of $16B. That is roughly 99.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

PhaseBio Pharmaceuticals reported $28M in net income as of June 2022. That compares with $-110M in the prior-year period — up 125.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $28M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for PhaseBio Pharmaceuticals, and consider following PHAS for alerts when major investors trade the stock.